

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ARIGEN PHARMACEUTICALS, INC.	09/12/2013
RECEIVING PARTY DATA	
Name:	NAI INC.
Street Address:	5-12, KITA AOYAMA 1-CHOME
City:	MINATO-KU, TOKYO
State/Country:	JAPAN
Postal Code:	107-0061
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8076302
CORRESPONDENCE DATA	
Fax Number:	(248)641-0270
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	248.641.1600
Email:	sslomzenski@hdp.com
Correspondent Name:	MICHAEL E. HILTON
Address Line 1:	P.O. BOX 828
Address Line 4:	BLOOMFIELD HILLS, MICHIGAN 48303
ATTORNEY DOCKET NUMBER:	7503-000023/US/NP
NAME OF SUBMITTER:	SANDRA L. SLOMZENSKI
Signature:	/Sandra L. SlomZenski/
Date:	10/03/2013
Total Attachments: 1 source=Assignment_NAI_5703-000023USNP#page1.tif	

CH \$40.00 8076302

PATENT

ASSIGNMENT

WHEREAS, by virtue of Assignment recorded in the United States Patent and Trademark Office, aRigen Pharmaceuticals, Inc. of 3-37, Akasaka 7-chome, Minato-ku, Tokyo 107-0052 Japan (hereinafter referred to as "Assignor") is the owner of United States Patent No. 8,076,302 for an invention entitled:

PYRIMIDINE NUCLEOSIDE DERIVATIVES AND SALTS THEREOF


ISSUED on December 13, 2011.

WHEREAS, NAI Inc. of 5-12, Kita aoyama 1-chome, Minato-ku, Tokyo 107-0061 Japan (hereinafter referred to as "Assignee") is desirous of acquiring from the said Assignor his right, title and interest in, and to the said United States patent.

NOW THEREFORE, in consideration of the sum of one dollar (US\$1.00) paid by the Assignee to the Assignor, the receipt of which is hereby acknowledged, the Assignor hereby sells, transfers and conveys to the Assignee of all the right, title and interest in, to and under the said patent to the Assignee.


Dated this 12th day of September, 2013.

aRigen Pharmaceuticals, Inc.




Gensuke TOKORO
President & CEO

Witness:



Masaichi YAMAMOTO
Member of the Board
Chief Scientific Officer



Hirofumi NAKAJIMA
Project Director
Research & Development Department